CROSSJECT (XPAR:ALCJ) FFO


XPAR:ALCJ CROSSJECT XPAR:ALCJ
40 GF Score
Price €1.63
GF Value €1.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:ALCJ
40GF Score
CROSSJECT XPAR:ALCJ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CROSSJECT (XPAR:ALCJ) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.63 is trading 35% above its estimated GF Value™ of €1.21. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for XPAR:ALCJ:

  • FFO:
  • GF Value™: €1.21 vs. price of €1.63 (35% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CROSSJECT Business Description

Other Exchanges 74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
40GF Score

Get the complete analysis for XPAR:ALCJ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price
€1.21
GF Value